Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 516-525

  Hinke, S A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMYD; GLUTAMATE DECARBOXYLASE 65; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; INJECTION SITE INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTOSIS; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUM COMPOUNDS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HUMANS; INJECTIONS, SUBCUTANEOUS; RECOMBINANT PROTEINS;

EID: 53249140520     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. 211250 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N ENGL J MED 1993 329 14 977-986
2. 241317 BioSyn Holding has rights to UCLA's GAD technology. SCRIP 1997 2219/20 23
3. 353988 Diamyd diabetes vaccine completes clinical trial. Diamyd Medical AB PRESS RELEASE 2000 January 31
4. 382244 GAD-Diamyd - more effective than insulin? Diamyd Medical AB PRESS RELEASE 2000 September 13
5. 431104 β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR LANCET 2001 358 9295 1749-1753
6. 453813 Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO DIABETES 1998 47 6 894-899
7. 459682 Preferential new share issue by Diamyd Medical AB realized SEK 30.5 million. Diamyd Medical AB PRESS RELEASE 2002 January 09
8. 459728 Diamyd Medical improves on license agreement with UCLA. Diamyd Medical AB PRESS RELEASE 2001 May 14
9. 459942 Quarterly report II - 99/00: 6 months report for Diamyd Medical AB (1 September 1999 - 29 February 2000). Diamyd Medical AB PRESS RELEASE 2000 May 03
10. 460240 Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6042, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Alleva DG, Gaur A, Jin L, Wegmann D, Gottleib PA DIABETES 2002 51 7 2126-2134
11. 463631 The NOD mouse model of type 1 diabetes: As good as it gets? Atkinson MA, Leiter EH NAT MED 1999 5 6 601-604
12. 492752 A phase II clinical trial involving alum-formulated GAD65 vaccination of GAD65-autoantibody positive adult diabetes patients. Lernmark A, Abdulahi P, Agardh C-D, Atkinson MA, Cilio C, Essen-Moller A, Harris RA, Hawa M, Kaufman DL, Klareskog L, Leslie RDG et al DIABETES 2003 52 Suppl 6 Abs 32-LB
13. 541501 Clinical evidence for safety, efficacy, and immunomodulation by a novel therapeutic intended for treatment of autoimmune diabetes. Agardh C-D, Cilio CM, Lethagen A, Lynch K, Leslie RDG, Palmer M, Harris RA, Robertson J, Lernmark A DIABETES 2004 53 Abs 272-OR
14. 563610 Diamyd starts larger trial in type 2 diabetes patients in Sweden. Diamyd Medical AB PRESS RELEASE 2004 October 07
15. 628605 Diamyd - a novel treatment for 10% of all type 2 diabetes patients - in a fully recruited phase II/III trial. Diamyd Medical AB PRESS RELEASE 2005 October 07
16. 641096 Diamyd Medical demonstrates safety of new GAD formulation in pre-clinical study. Diamyd Medical AB PRESS RELEASE 2005 December 15
17. 641891 Diamyd Medical appoints Protein Sciences 'USA' for production of its lead therapeutic diabetes vaccine for phase III-trials and to submit an IND to the FDA. Diamyd Medical AB PRESS RELEASE 2005 December 19
18. 644016 Protein Sciences raises $6 million. Protein Sciences Corp PRESS RELEASE 2006 January 09
19. 500-585. Han G, Li Y, Wang J, Wang R, Chen G, Song L, Xu R, Yu M, Wu X, Qian J, Shen B J IMMUNOL 2005 174 8 4516-4524
20. 689625 Neurocrine Biosciences announces results from follow-up phase II study with its orally active GnRH receptor antagonist in endometriosis. Neurocrine Biosciences Inc PRESS RELEASE 2006 September 12
21. 744039 Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV J IMMUNOL 2001 166 3 2122-2132
22. 744041 Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. Tisch R, Wang B, Serreze DV J IMMUNOL 1999 163 3 1178-1187
23. 744043 Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A J DIABETES COMPLICAT 2005 19 4 238-246
24. 804957 GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Bekris LM, Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen AL, Lernmark A, Robertson JA, Hampe CS DIABETIC MED 2007 24 5 521-526
25. 806791 Diamyd diabetes study invalidated. Diamyd Medical AB PRESS RELEASE 2007 June 18
26. 806792 Diamyd continues invalidated study. Diamyd Medical AB PRESS RELEASE 2007 June 19
27. 832400 Diamyd Medical: US National Institutes of Health announces plans to sponsor a type 1 diabetes trial with the experimental Diamyd diabetes vaccine. Diamyd Medical AB PRESS RELEASE 2007 September 21
28. 862959 Diamyd Medical: Diamyd files US IND for phase III trial with diabetes vaccine. Diamyd Medical AB PRESS RELEASE 2007 December 21
29. 862985 NCT00529399: Effects of recombinant human glutamic acid decarboxylase. CLINICALTRIALS.GOV 2007
30. 868645 Diamyd initiates European submission for phase III studies with diabetes vaccine. Diamyd Medical AB PRESS RELEASE 2008 January 18
31. 872521 First quarterly report for Diamyd Medical AB, fiscal year 2007/2008. Diamyd Medical AB PRESS RELEASE 2008 January 31
32. 877162 NCT00615264: Efficacy study of DiaPep277 in newly diagnosed type 1 diabetes patients (DIA-AID). CLINICALTRIALS.GOV 2008
33. 877600 The Swedish GAD-vaccination trial: Outcomes of a phase II safety and efficacy trial with Diamyd for preservation of β cell function in children with T1D. Ludvigsson J, Casas R, Vaarala O, Forsander G, Ivarsson SA, Johansson C, Lindh A, Nilsson NO, Aman J DIABETOLOGIA 2006 49 Suppl 1 Abs 0236
34. 880516 Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H DIABETES CARE 2004 27 5 1047-1053
35. 886377 Diamyd Medical: Diamyd gets authorization to begin phase III study in the US. Diamyd Medical AB PRESS RELEASE 2008 March 14
36. 887845 Diamyd diabetes vaccine receives approval to start phase III trials in Europe. Diamyd Medical AB PRESS RELEASE 2008 March 19
37. 898419 Diamyd strengthens financial position and executes a fully subscribed direct placement. Diamyd Medical AB PRESS RELEASE 2008 April 21
38. 915882 Structural and functional considerations of GABA in islets of Langerhans. β-cells and nerves. Sorenson RL, Garry DG, Brelje TC DIABETES 1991 40 11 1365-1374
39. 915883 Ontogeny and tissue distribution of human GAD expression. Mally MI, Cirulli V, Otonkoski T, Soto G, Hayek A DIABETES 1996 45 4 496-501
40. 915885 Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues. Chessler SD, Lernmark A J BIOL CHEM 2000 275 7 5188-5192
41. 915886 Expression of glutamic acid decarboxylase (GAD) in the α, β and δ cells of normal and diabetic pancreas: Implications for the pathogenesis of type I diabetes. Vives-Pi M, Somoza N, Vargas F, Armengol P, Sarri Y, Wu JY, Pujol-Borrell R CLIN EXP IMMUNOL 1993 92 3 391-396
42. 915887 Differential expression of glutamic acid decarboxylase in rat and human islets. Petersen JS, Russel S, Marshall MO, Kofod H, Buschard K, Cambon N, Karlsen AE, Boel E, Hagopian WA, Hejnaes KR DIABETES 1993 42 3 484-495
43. 915893 The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, Atkinson MA NAT MED 1996 2 2 148-153
44. 915970 Glutamic acid decarboxylase - Gene to antigen to disease. Lernmark A J INTERN MED 1996 240 5 259-277
45. 915973 UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R LANCET 1997 350 9087 1288-1293
46. 915974 Latent autoimmune diabetes in adults (LADA) should be less latent. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC DIABETOLOGIA 2005 48 11 2206-2212
47. 915979 Prediction and prevention of type 1 diabetes: Progress, problems, and prospects. Skyler JS CLIN PHARMACOL THER 2007 81 5 768-771
48. 915980 Immunotherapy of insulin-dependent diabetes mellitus. Bach JF CURR OPIN IMMUNOL 2001 13 5 601-605
49. 915984 Tolerogenic strategies to halt or prevent type 1 diabetes. Cooke A, Phillips JM, Parish NM NAT IMMUNOL 2001 2 9 810-815
50. 916035 Treatment with GAD65 or BSA does not protect against diabetes in BB rats. Petersen JS, Mackay P, Plesner A, Karlsen A, Gotfredsen C, Verland S, Michelsen B, Dyrberg T AUTOIMMUNITY 1997 25 3 129-138
51. 916043 GAD65 and insulin B chain peptide (9-23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat. Bieg S, Hanlon C, Hampe CS, Benjamin D, Mahoney CP AUTOIMMUNITY 1999 31 1 15-24
52. 916045 Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV NATURE 1993 366 6450 69-72
53. 916048 Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO NATURE 1993 366 6450 72-75
54. 916051 Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R, Arita S, Evans C, Atkinson MA, Mullen Y, Sarvetnick N et al NAT MED 1996 2 12 1348-1353
55. 916052 Characterization of novel T-cell epitopes on 65 kDa and 67 kDa glutamic acid decarboxylase relevant in autoimmune responses in NOD mice. Zechel MA, Elliott JF, Atkinson MA, Singh B J AUTOIMMUN 1998 11 1 83-95
56. 916053 Regulatory cytokine production stimulated by DNA vaccination against an altered form of glutamic acid decarboxylase 65 in nonobese diabetic mice. Glinka Y, De Pooter R, Croze F, Prud'homme GJ J MOL MED 2003 81 3 175-184
57. 916054 Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Jun HS, Chung YH, Han J, Kim A, Yoo SS, Sherwin RS, Yoon JW DIABETOLOGIA 2002 45 5 668-676
58. High Treg. Casas R, Hedman M, Faresjo M, Ludvigsson J DIABETES 2007 56 Suppl 1 Abs 1242-P
59. 916056 Specific immune response to GAD65 in type 1 diabetic children treated with GAD65 (Diamyd). Faresjo M, Hedman M, Casas R, Axelsson S, Ludvigsson J DIABETOLOGIA 2007 50 Suppl 1 S30-S31
60. 916062 Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL J EXP MED 1996 183 4 1561-1567
61. 916065 Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM PROC NATL ACAD SCI USA 2004 101 15 5680-5685
62. 916069 Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. Plesner A, Worsaae A, Dyrberg T, Gotfredsen C, Michelsen BK, Petersen JS J AUTOIMMUN 1998 11 4 335-341
63. 916076 Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. Pedotti R, Sanna M, Tsai M, DeVoss J, Steinman L, McDevitt H, Galli SJ BMC IMMUNOL 2003 4 2
64. 916078 Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet β-cells. Waldrop MA, Suckow AT, Marcovina SM, Chessler SD ENDOCRINOLOGY 2007 148 10 4572-4578
65. 916084 β Cell function and metabolic control during two years of follow-up after GAD65 dose-escalation immunomodulation in adult-onset autoimmune diabetes. Agardh CD, Lethagen A, Cilio CM, Lynch K, Palmer M, Leslie DRG, Harris RA, Robertson JA, Lernmark A DIABETES 2006 55 Abs 1173-P
66. 916085 Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL DIABETES 2005 54 Suppl 2 97-107
67. 916089 Finding GAD: Early detection of β-cell injury. Hinke SA ENDOCRINOLOGY 2007 148 10 4568-4571
68. 916110 A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. Shah SC, Malone JI, Simpson NE N ENGL J MED 1989 320 9 550-554
69. 916111 Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E DIABETES CARE 2005 28 5 1068-1076
70. 916138 National diabetes fact sheet - United States. Centers for Disease Control and Prevention COMPANY PUBLICATION 2008 October 26
71. 931798 NCT00723411: A phase III study to investigate the impact of Diamyd in patients newly diagnosed with type 1 diabetes. Diamyd Therapeutics AB CLINICALTRIALS.GOV 2008
72. 932195 Diamyd Medical - Scientific platform. Diamyd Medical AB COMPANY WORLD WIDE WEB SITE 2008 August 06
73. 932491 Diamyd Medical - Company information. Diamyd Medical AB COMPANY WORLD WIDE WEB SITE 2008 August 06
74. 933764 Diamyd Medical: Diamyd prevents insulin treatment in LADA patients. Diamyd Medical AB PRESS RELEASE 2008 August 11
75. 937499 GAD65 vaccination significantly reduces insulin dependence at five years follow-up in a dose escalating study in adult-onset autoimmune diabetes patients. Agardh C-D, Lynch K, Palmér M, Link K, Lernmark Å EUR ASSOC STUDY DIABETES ANN MEET 44 September 7-10 Abs 565
76. 939181 Insect cells as hosts for the expression of recombinant glycoproteins. Altmann F, Staudacher E, Wilson IB, März L GLYCOCONJUGATE J 1999 16 2 109-123